Health on MSN

What's the life expectancy for complement 3 glomerulopathy—and how does it affect quality of life?

Medically reviewed by Michael Menna, DO Complement 3 glomerulopathy is a rare disease caused by a buildup of proteins in the ...
Health on MSN

What causes complement 3 glomerulopathy, a rare kidney condition?

Medically reviewed by David Ozeri, MD Complement 3 glomerulopathy (C3G) is a rare kidney disorder—in many cases, the exact ...
Frontiers

The Role of Glial Cells in the Pathophysiology and Treatment of Alzheimer's Disease

The involvement of glial cells in Alzheimer's disease (AD) has been mostly viewed as a secondary adaptive response to ...
BioSpace

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...
Pharmabiz

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

Omeros Corporation, an innovative biotechnology company, announced that the US Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...
MarketWatch

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
MarketWatch

Omeros Gets FDA Approval of Yartemlea

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
Times Argus

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the effector enzyme of the lectin pathway, blocking pathway activation while preserving ...